Vicore Pharma Holding AB (publ) (VCRE) is in Healthcare, Biotechnology, based in Sweden, listed on NasdaqCM. Market cap 248.41M USD. 52-week range 7.88 to 17.80 USD. Data as of 2026-10-09.
Vicore Pharma Holding AB (publ), a clinical-stage pharmaceutical company, develops therapies for the treatment of respiratory diseases in Sweden. The company develops Buloxibutid (C21), an orally available small molecule angiotensin II type 2 receptor agonist (ATRAG) that is in Phase II clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF), as well as in Phase I clinical trial for treating pulmonary hypertension. It also developing Almee, an investigational medical device in ...